Recursion Pharmaceuticals News - August 2026

🟢 Recursion Pharmaceuticals is trading 10.36% up today after positive Phase 3 melanoma cancer-vaccine results

Recursion Pharmaceuticals is trading 10.36% up at $3.41, mainly as biotech stocks rallied after positive Phase 3 melanoma cancer-vaccine results from Moderna...

Recursion Pharmaceuticals Inc Q2 2026 Earnings Preview: What Analysts Expect on August 05, 2026

Analysts expect Recursion Pharmaceuticals to report a Q2 2026 consensus revenue of $10.97 million and an EPS loss of $0.25, with the stock currently trading...